ImmunoCellular Therapeutics Chooses PharmaCell as Contract Manufacturing Partner for Its Phase III Program in Europe

PharmaCell has finalized an agreement with ImmunoCellular Therapeutics to support its pivotal Phase III clinical trial in Europe with ICT-107. ICT 107 is a dendritic cell-based vaccine developed for glioblastoma multiforme, one of the commonest and deadliest forms of brain cancer. Under the terms of the agreement, PharmaCell will perform a Technology Transfer from its US-based contract manufacturing partner to its newly acquired Geleen facility (The Netherlands), and support the subsequent clinical trial with ICT-107.

Andrew Gengos, CEO of ImmunoCellular Therapeutics explained: “We are pleased to engage with PharmaCell who have a proven ability to support companies in establishing a robust manufacturing capability in Europe in line with the strict standards of the regulatory authorities for Phase III and early-stage commercial manufacturing for ATMPs (Advanced Therapy Medicinal Products).”

Alexander Vos, CCEOr of PharmaCell, said: “We are excited that ImmunoCellular Therapeutics, a global leader in cancer immunotherapy, have decided to work with us. Their decision confirms that our new Geleen facility is indeed viewed by industry experts as meeting the requirements and client expectations for late clinical stage and commercial manufacturing for ATMPs. We look forward to support ImmunoCellular in their effort to develop ICT-107 for the benefit of European patients.”